Analysts' Actions: AAPL, INTC, GS, BAC, YHOO

NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPS

Alpha Natural ( ANR) rated new Buy at Sterne Agee ANR was initiated with a Buy rating, Sterne Agee said. $35 price target. Company remains leveraged to growth in the met coal market.

Apple ( AAPL) estimates, target increased at Morgan Stanley. AAPL estimates were raised through 2013. iPhone continues to drive growth. Overweight rating and new $480 price target.

Apple estimates increased at UBS. AAPL estimates raised through 2013. iPhone purchase and carrier launch delays ahead of 4S cause shortfall. Maintain $510 price target and Buy rating.

Arch Coal ( ACI) rated new Neutral at Sterne Agee. $23 price target. Company faces integration challenges.

Bank of America ( BAC) estimates lowered at Sterne Agee. BAC estimates were cut through 2013. Company will take a while to turn its business around. Neutral rating and $7 price target.

Bank of America numbers lowered at UBS. Shares of BAC now seen reaching $7. Estimates also lowered on weaker capital markets and lower reserve releases. Neutral rating.

Chipotle Mexican Grill ( CMG) rated new Neutral at UBS. $345 price target. Solid near term outlook, but appears appropriately valued.

Citrix Systems ( CTXS) upgraded at Needham from Hold to Buy. $85 price target. Spending on data center projects should remain strong.

Coca-Cola ( KO) estimates lowered at Credit Suisse through 2013. Currency changes are cutting into earnings. Outperform rating and $95 price target.

Coca-Cola numbers lowered at UBS. Shares of KO now seen reaching $73. Estimates also lowered on currency and spending impact. Maintain Buy rating.

Cree ( CREE) estimates, target reduced at Sterne Agee. Shares of CREE now seen reaching $52. Estimates also cut, to match the company's new guidance. Buy rating.

Cree estimates, target lowered at UBS. Shares of CREE now seen reaching $29.50. Estimates also lowered as outlook suggest industry is still bottoming. Neutral rating.

EMC ( EMC) estimates upped at Sterne Agee through 2012. Company is gaining market share and realizing higher margins. Buy rating and $30 price target.

Forest Laboratories ( FRX) numbers reduced at Goldman. Shares of FRX now seen reaching $30. Estimates also cut, given the company's negative operating leverage.

Forest Labs estimates, target cut at UBS. Shares of FRX now seen reaching $32. Estimates also lowered on below guidance launches. Neutral rating.

Fossil ( FOSL) rated new Buy at Citigroup. $114 price target. Strategic positions and minimal competition have yielded moderately priced watch market leadership.

Goldman Sachs ( GS) estimates reduced at ThinkEquity through 2012. Company will likely continue to see lower capital markets activity. Outperform rating and $181 price target.

Goldman Sachs estimates, target cut at UBS. Shares of GS now seen reaching $140. Estimates also lowered on weaker expectations of capital markets activity. Buy rating.

Grainger ( GWW) estimates, target raised at UBS. Shares of GWW now seen reaching $177. Estimates also increased on solid inflation management and growth initiatives gaining. Neutral rating.

Harley-Davidson ( HOG) numbers cut at Goldman. Shares of HOG now seen reaching $44. Estimates also reduced, given higher operating costs. Neutral rating.

Harley-Davidson estimates cut at UBS through 2012. Q3 margins miss and FY11 margin guidance revised down. Maintain $39 price target and Neutral rating.

Hospira ( HOSP) estimates, target cut at Citigroup. Shares of HOSP now seen reaching $30. Estimates also lowered on manufacturing issus at the Rocky Mount facility. Neutral rating.

Human Genome ( HGSI) numbers cut at ThinkEquity. Shares of HGSI now seen reaching $26. Estimates also reduced, given a modest Benlysta launch. Buy rating.

Intel ( INTC) estimates, target raised at Citigroup. Shares of INTC now seen reaching $27.50. Estimates also increased as company is executing well, but market disparity a lingering concern. Buy rating.

Intel estimates, target raised at Goldman. Shares of INTC now seen reaching $22. Estimates also increased, as higher sales is driving margin expansion.

Intel estimates, target raised at UBS. Shares of INTC now seen reaching $30. Estimates also increased as solid execution offsets macro weakness. Buy rating.

Intuitive Surgical ( ISRG) numbers boosted at Goldman. Shares of ISRG now seen reaching $412. Estimates also upped, to match the company's new guidance. Neutral rating.

Juniper ( JNPR) estimates, target cut at Credit Suisse. Shares of JNPR now seen reaching $25. Estimates also reduced, given the company's new guidance. Neutral rating.

Juniper Networks estimates lowered at UBS through 2012. Strong 3Q bookings and visibility better into 1Q, but still risk. Maintain $24 price target and Neutral rating.

Juniper Networks downgraded at Wells from Outperform to Market Perform. Growth outlook is deteriorating.

Netflix ( NFLX) estimates reduced at Credit Suisse. NFLX estimates were cut through 2013. Company is realizing slower domestic subscriber growth. Outperform rating and $240 price target.

Parker Hannifin ( PH) numbers raised at Goldman. Shares of PH now seen reaching $81. Estimates also increased, given better business momentum. Neutral rating.

Rightnow Technologies ( RNOW) downgraded at Stifel from Buy to Hold. Valuation call.

Sotheby's ( BID) rated new Neutral at Citigroup. $35 price target. High trust agency model with low inventory risk.

State Street ( STT) numbers increased at Goldman. STT estimates were raised through 2013. Company is gaining market share and keeping a tight lid on costs. Buy rating and new $48 price target.

Steel Dynamics ( STLD) numbers lowered at Jefferies. STLD estimates were cut through 2012. Company is leveraged to lower steel demand. Buy rating and new $16 price target.

Steven Madden ( SHOO) rated new Buy at Citigroup. $41 price target. Accelerating sales/EPS despite economy.

Under Armour ( UA) numbers raised at Jefferies. Shares of UA now seen reaching $73. Estimates also increased, as the company should continue to expand margins. Buy rating.

UnitedHealth ( UNH) estimates increased at Credit Suisse. UNH estimates were raised through 2012. Company continues to deliver solid growth. Outperform rating and $72 price target.

UnitedHealth estimates raised at UBS through 2011. Among best positioned to navigate uncertainties heading into 2014. Maintain $58 price target and Buy rating.

US Steel ( X) rated new Market Perform at Wells Fargo. Company continues to face macro headwinds.

Union Drilling ( UDRL) downgraded to sell at TheStreet Ratings.

Vera Bradley ( VRA) rated new Buy at Citigroup. $51 price target. See sales upside on industry leading comparable same store sales.

VF Corp. ( VFC) estimates raised at UBS through 2012. TBL, FX, and North Face upside. Maintain $135 price target and Buy rating.

Whole Foods ( WFM) upgraded at Jefferies to Buy. $90 price target. Estimates also boosted, as the company continues to deliver comp sales growth.

WW Grainger ( GWW) numbers upped at Goldman. GWW estimates were boosted through 2013. Company is realizing higher margins. Neutral rating and new $176 price target.

Yahoo! ( YHOO) estimates upped at Credit Suisse through 2012. Company is realizing higher margins. Neutral rating and $19 price target.

Yahoo! estimates increased at UBS through 2012. Mixed quarter as investors remain focused on potential event. Maintain $16 price target and Neutral rating.

Zygo ( ZIGO) upgraded to buy at TheStreet Ratings.

Related links:


This article was written by a staff member of TheStreet.